(Q39222370)

10 September 2017

The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer (English)

1 reference

10 September 2017

J Raemaekers

1

1 reference

10 September 2017

H Kluin-Nelemans

2

1 reference

10 September 2017

I Teodorovic

3

1 reference

10 September 2017

C Meerwaldt

4

1 reference

10 September 2017

E Noordijk

5

1 reference

10 September 2017

J Thomas

6

1 reference

10 September 2017

M van Glabbeke

7

1 reference

10 September 2017

M Henry-Amar

8

1 reference

10 September 2017

P Carde

9

1 reference

10 September 2017

language of work or name

1 reference

1 March 2002

1 reference

European Journal of Cancer

10 September 2017

1 reference

10 September 2017

38 Suppl 4

1 reference

10 September 2017

S107-13

1 reference

Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease

10 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

A multivariate analysis of prognostic factors in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Long-term toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curi

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Reproducibility and prognostic value of different non-Hodgkin's lymphoma classifications: study based on the clinicopathologic relations found in the EORTC trial (20751).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Report on the EORTC lymphoma trial 20751

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade non-Hodgkin's lymphoma (NHL): the 1980-1985 EORTC trial. The EORTC Lymphoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900446-4

7 January 2021

10.1016/S0959-8049(01)00446-4

Identifiers

DOI

1 reference

release_7wa5uwurqbcirajmoklot6e6bu

10 September 2017

0 references

1 reference